185 related articles for article (PubMed ID: 24890858)
1. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Ciombor KK; Feng Y; Benson AB; Su Y; Horton L; Short SP; Kauh JS; Staley C; Mulcahy M; Powell M; Amiri KI; Richmond A; Berlin J
Invest New Drugs; 2014 Oct; 32(5):1017-27. PubMed ID: 24890858
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Argiris A; Ghebremichael M; Burtness B; Axelrod RS; Deconti RC; Forastiere AA
Cancer; 2011 Aug; 117(15):3374-82. PubMed ID: 21246525
[TBL] [Abstract][Full Text] [Related]
3. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Kim GP; Mahoney MR; Szydlo D; Mok TS; Marshke R; Holen K; Picus J; Boyer M; Pitot HC; Rubin J; Philip PA; Nowak A; Wright JJ; Erlichman C
Invest New Drugs; 2012 Feb; 30(1):387-94. PubMed ID: 20839030
[TBL] [Abstract][Full Text] [Related]
4. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
[TBL] [Abstract][Full Text] [Related]
5. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS; Wheler JJ; Naing A; Jackson EF; Janku F; Hong D; Ng CS; Tannir NM; Lawhorn KN; Huang M; Angelo LS; Vishwamitra D; Hess K; Howard AN; Parkhurst KL; Amin HM; Kurzrock R
Oncotarget; 2014 Nov; 5(21):10280-92. PubMed ID: 25373733
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Takamatsu Y; Sunami K; Muta T; Morimoto H; Miyamoto T; Higuchi M; Uozumi K; Hata H; Tamura K;
Int J Hematol; 2013 Aug; 98(2):179-85. PubMed ID: 23832805
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS; Anderson T; Mietzel MA; Harvey CK; Wear SM; Barrickman JC; Tendler CL; Esseltine DL; Kelley SL; Kaminski MS; Anderson KC; Richardson PG
Blood; 2011 Jul; 118(3):535-43. PubMed ID: 21596852
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Lara PN; Longmate J; Reckamp K; Gitlitz B; Argiris A; Ramalingam S; Belani CP; Mack PC; Lau DH; Koczywas M; Wright JJ; Shepherd FA; Leighl N; Gandara DR
Clin Lung Cancer; 2011 Jan; 12(1):33-7. PubMed ID: 21273177
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Orlowski RZ; Voorhees PM; Garcia RA; Hall MD; Kudrik FJ; Allred T; Johri AR; Jones PE; Ivanova A; Van Deventer HW; Gabriel DA; Shea TC; Mitchell BS; Adams J; Esseltine DL; Trehu EG; Green M; Lehman MJ; Natoli S; Collins JM; Lindley CM; Dees EC
Blood; 2005 Apr; 105(8):3058-65. PubMed ID: 15626743
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
14. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
Irvin WJ; Orlowski RZ; Chiu WK; Carey LA; Collichio FA; Bernard PS; Stijleman IJ; Perou C; Ivanova A; Dees EC
Clin Breast Cancer; 2010 Dec; 10(6):465-70. PubMed ID: 21147690
[TBL] [Abstract][Full Text] [Related]
16. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Hoang T; Campbell TC; Zhang C; Kim K; Kolesar JM; Oettel KR; Blank JH; Robinson EG; Ahuja HG; Kirschling RJ; Johnson PH; Huie MS; Wims ME; Larson MM; Hernan HR; Traynor AM
Invest New Drugs; 2014 Feb; 32(1):195-9. PubMed ID: 23728919
[TBL] [Abstract][Full Text] [Related]
18. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
Chang JE; Peterson C; Choi S; Eickhoff JC; Kim K; Yang DT; Gilbert LA; Rogers ES; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Br J Haematol; 2011 Oct; 155(2):190-7. PubMed ID: 21848883
[TBL] [Abstract][Full Text] [Related]
19. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Falchook GS; Duvic M; Hong DS; Wheler J; Naing A; Lim J; Kurzrock R
Cancer Chemother Pharmacol; 2012 May; 69(5):1117-26. PubMed ID: 22205203
[TBL] [Abstract][Full Text] [Related]
20. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
